When developing vaccines against COVID-19, ‘fast is slow, and slow is fast’

Bypassing clinical trials for a potential SARS-CoV-2 vaccine would be “catastrophic,” says Science Advances deputy editor Douglas Green in this Editorial. Instead, it’s vital to take time to ensure any vaccine candidate’s safety and investigate potential adverse